The FDA has granted Priority Review to durvalumab for the treatment of resectable, early-stage and locally advanced (Stage II-IVA) gastric and gastroesophageal junction cancers.

There have been 402 “attacks on science” in the first 6 months of President Donald Trump’s second term, a new report suggests.